secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001193125-25-281531
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics Q3 2025: ORLYNVAH launch nets $0.4M revenue; cash runway extended to Q2 2026
--------------------------------------------------------------------------------

- Net product revenue of $0.4M from ORLYNVAH launch in August 2025; 2026 sales guidance $5M-$15M.
- Cash and equivalents $11.0M as of Sep 30, 2025; additional $2.6M raised Oct-Nov 2025 extends runway into Q2 2026.
- GAAP net loss $9.0M ($0.81 diluted EPS); non-GAAP net loss $7.3M vs. $6.1M and $4.8M in Q3 2024.
- SG&A expenses rose to $6.5M from $1.8M YoY due to commercialization; R&D fell to $1.3M.
- Granted patents in China and Mexico covering sulopenem combinations; IDWeek posters presented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/0001193125-25-281531-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/itrm-20251114.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-281531

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer